APLIF News and Press, Appili Therapeutics Inc From 06/24/25

Appili Therapeutics Inc (APLIF) is expected to report for quarter end 2025-03-31

2025-06-09 09:09:56 ET Aditxt (NASDAQ: ADTX) has appointed Saundra Pelletier, CEO of Evofem Biosciences (OTCPK: EVFM), to its Board of Directors as the company advances toward commercialization and sharpens its focus on women’s health. Pelletier brings more than 30 years of globa...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, May 30, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “ Company ” or “ Appili ”), a biopharmaceuti...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, May 19, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “ Company ” or “ Appili ”), a biopharmaceuti...

2025-05-02 09:40:00 ET Aditxt (NASDAQ: ADTX) announced that Chief Innovation Officer Dr. Shahrokh Shabahang and Adimune Co-CEO Dr. Friedrich Kapp will participate in today’s Aditxt Weekly Update to discuss recent progress on ADI-100 , the lead therapeutic candidate of its wholly ...

HALIFAX, Nova Scotia, May 01, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced a p...

New patents provide additional composition of matter and methods of use claims, strengthening the protection for liquid oral taste-masked reformulation, LIKMEZ New subject matter listed in the U.S. Food and Drug Administration’s (“FDA”) Orange Book HALIFAX, Nova...

2025-04-17 10:15:00 ET Aditxt (NASDAQ: ADTX) announced that Dr. Charles Howe of the Mayo Clinic will join the Company’s Weekly Update on May 2, 2025, to discuss key findings from a newly announced preclinical study of ADI-100 , the lead therapeutic candidate from Aditxt’s ...

2025-04-16 09:15:00 ET Aditxt (NASDAQ: ADTX) announced that its subsidiary Pearsanta has received Institutional Review Board approval to initiate a clinical study evaluating the Mitomic Endometriosis Test (MET), a blood-based diagnostic aimed at early detection of endometriosis. The stu...

2025-04-14 09:35:00 ET Aditxt (NASDAQ: ADTX) announced that a Mayo Clinic-led study has validated preclinical findings for ADI-100, the lead autoimmune therapy candidate developed by its subsidiary Adimune Inc. The study confirmed ADI-100’s ability to induce immune tolerance to g...